Health and Healthcare

Amgen : AMGN

All Amgen Articles

708 Articles

Chris Lange | Oct 28, 2015 at 11:25 AM EDT

What to Expect From Amgen Earnings

Amgen is scheduled to report its third-quarter financial results after the markets close on Wednesday.

Chris Lange | Oct 27, 2015 at 8:10 AM EDT

Short Sellers Become More Selective on Leading Biotechs

The October 15 short interest data have been compared with the previous figures, and short interest mixed in these selected…

Chris Lange | Oct 23, 2015 at 1:35 PM EDT

Why Amgen’s Future Is Looking Bright

Amgen is slowly getting closer to an FDA final decision for its first-of-a-kind cancer therapy, talimogene laherparepvec (T-Vec).

Lee Jackson | Oct 20, 2015 at 10:05 AM EDT

Q3 Worst for Biotech in 7 Years: Which Large Cap Leaders to Buy Now

Cowen says the way to play biotech is with large cap sector leaders that can beat earnings estimates. It also…

Chris Lange | Oct 12, 2015 at 8:20 AM EDT

Short Sellers Increase Bets in Major Biotechs

The September 30 short interest data have been compared with the previous figures, and short interest increased in most of…

Lee Jackson | Oct 9, 2015 at 10:05 AM EDT

UBS Loves These 3 Top Biotech Stock Leaders Into Q3 Earnings

Given the massive beat-down in the sector, if these companies surpass earnings expectations, the upside could be sizable.

Jon C. Ogg | Sep 29, 2015 at 11:25 AM EDT

Independent Research Sees 3 Top Health and Biotech Stocks as Oversold

Independent research firm Argus has reviews of three of health care picks from its own Focus List in which it…

Chris Lange | Sep 26, 2015 at 9:25 AM EDT

How the Top Biotechs Handled the Valuation Shock

24/7 Wall St. has taken a look at some of the largest biotech companies and highlighted the damage that a…

Chris Lange | Sep 25, 2015 at 8:05 AM EDT

Short Sellers Increase Bets in Major Biotech

The September 15 short interest data have been compared with the previous figures, and short interest in these selected stocks…

Chris Lange | Sep 16, 2015 at 1:20 PM EDT

Fitch: Gradual Conversion Begins as First Biosimilar Hits US Market

According to Fitch Ratings, biosimilars are beginning to take share from their reference biologics. This is seen in the debut…

Chris Lange | Sep 16, 2015 at 11:05 AM EDT

Meet the Newest Biotech Collaboration: Amgen and Xencor

Amgen and Xencor have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas…

Chris Lange | Sep 11, 2015 at 8:05 AM EDT

Short Sellers Increase Bets in Major Biotechs

The short interest data are out for the August 31 settlement date. Short interest in the selected biotech stocks increased…

Jon C. Ogg | Sep 8, 2015 at 9:10 AM EDT

Top Analyst Upgrades and Downgrades: Amgen, Dow, Fitbit, Office Depot, SanDisk, Wells Fargo, Yum and Many More

Tuesday’s top analyst upgrades, downgrades and initiations include Amgen, Dow Chemical, Fitbit, Office Depot, SanDisk, Wells Fargo and Yum! Brands.

Chris Lange | Aug 28, 2015 at 10:25 AM EDT

How Amgen Can Disrupt the Market for Cholesterol Drugs

Amgen has the potential to disrupt the market for cholesterol drugs with the newest addition to its drug portfolio.

Chris Lange | Aug 26, 2015 at 8:55 AM EDT

Short Sellers Become More Focused in Major Biotechs

The short interest data are out for the August 14 settlement date. Biotech companies are considered a riskier group of…

1 … 24 25 26 27 28 … 48

Amgen : AMGN

All Amgen Articles

What to Expect From Amgen Earnings

Short Sellers Become More Selective on Leading Biotechs

Why Amgen’s Future Is Looking Bright

Q3 Worst for Biotech in 7 Years: Which Large Cap Leaders to Buy Now

Short Sellers Increase Bets in Major Biotechs

UBS Loves These 3 Top Biotech Stock Leaders Into Q3 Earnings

Independent Research Sees 3 Top Health and Biotech Stocks as Oversold

How the Top Biotechs Handled the Valuation Shock

Short Sellers Increase Bets in Major Biotech

Fitch: Gradual Conversion Begins as First Biosimilar Hits US Market

Meet the Newest Biotech Collaboration: Amgen and Xencor

Short Sellers Increase Bets in Major Biotechs

Top Analyst Upgrades and Downgrades: Amgen, Dow, Fitbit, Office Depot, SanDisk, Wells Fargo, Yum and Many More

How Amgen Can Disrupt the Market for Cholesterol Drugs

Short Sellers Become More Focused in Major Biotechs

Analysts Say This Robotics Stock Could Be One of 2026’s Biggest Industrial Winners

If Social Security Cuts Benefits, Here’s Who Might Get Hurt the Most

Peter Thiel Turned a $2,000 Roth IRA Into $5 Billion and Will Never Owe a Penny of Tax. The Same Rules Apply to Your Account

If Social Security Cuts Benefits, Here's Who Might Get Hurt the Most

Peter Thiel Turned a $2,000 Roth IRA Into $5 Billion and Will Never Owe a Penny of Tax. The Same Rules Apply to Your Account

Analysts Say This Robotics Stock Could Be One of 2026’s Biggest Industrial Winners

If Social Security Cuts Benefits, Here’s Who Might Get Hurt the Most

Amgen : AMGN

All Amgen Articles

What to Expect From Amgen Earnings

Short Sellers Become More Selective on Leading Biotechs

Why Amgen’s Future Is Looking Bright

Q3 Worst for Biotech in 7 Years: Which Large Cap Leaders to Buy Now

Short Sellers Increase Bets in Major Biotechs

UBS Loves These 3 Top Biotech Stock Leaders Into Q3 Earnings

Independent Research Sees 3 Top Health and Biotech Stocks as Oversold

How the Top Biotechs Handled the Valuation Shock

Short Sellers Increase Bets in Major Biotech

Fitch: Gradual Conversion Begins as First Biosimilar Hits US Market

Meet the Newest Biotech Collaboration: Amgen and Xencor

Short Sellers Increase Bets in Major Biotechs

Top Analyst Upgrades and Downgrades: Amgen, Dow, Fitbit, Office Depot, SanDisk, Wells Fargo, Yum and Many More

How Amgen Can Disrupt the Market for Cholesterol Drugs

Short Sellers Become More Focused in Major Biotechs

Analysts Say This Robotics Stock Could Be One of 2026’s Biggest Industrial Winners

If Social Security Cuts Benefits, Here’s Who Might Get Hurt the Most

Peter Thiel Turned a $2,000 Roth IRA Into $5 Billion and Will Never Owe a Penny of Tax. The Same Rules Apply to Your Account

Featured Reads

If Social Security Cuts Benefits, Here's Who Might Get Hurt the Most

Peter Thiel Turned a $2,000 Roth IRA Into $5 Billion and Will Never Owe a Penny of Tax. The Same Rules Apply to Your Account